Your browser doesn't support javascript.
loading
PD-L1+ macrophages suppress T cell-mediated anticancer immunity.
Liu, Peng; Zhao, Liwei; Kroemer, Guido; Kepp, Oliver.
Affiliation
  • Liu P; Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
  • Zhao L; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
  • Kroemer G; Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
  • Kepp O; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
Oncoimmunology ; 13(1): 2338951, 2024.
Article in En | MEDLINE | ID: mdl-38590800
ABSTRACT
Recently, we showed that an autologous DC-based vaccine induces an increase in immunosuppressive PD-L1+ tumor-associated macrophages (TAM) both in the tumor and the tumor draining lymph nodes, thereby blunting the efficacy of therapeutic immunization. Only the combination of the DC vaccine with anti-PD-L1 immune checkpoint inhibition, but not the use of antibodies targeting PD-1 alone, was able to set off CD8+ cytotoxic T lymphocyte (CTL)-mediated tumor suppression in mice. In sum, we delineated a PD-L1 checkpoint blockade-based strategy to avoid TAM-induced T cell exhaustion during DC vaccine therapy.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Vaccines / B7-H1 Antigen Limits: Animals Language: En Journal: Oncoimmunology Year: 2024 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Vaccines / B7-H1 Antigen Limits: Animals Language: En Journal: Oncoimmunology Year: 2024 Type: Article Affiliation country: France